

- Kenter CG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med* 2009;361:1838–1847.
- Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. *Cytokine* 2004;28:109–123.
- Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. *J Clin Oncol* 2005;23:6043–6053.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–2454.
- Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin Cancer Res* 2011;17:4550–4557.
- Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *J Clin Oncol* 2011;29:917–924.
- Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. *Proc Natl Acad Sci U S A* 1997;94:1914–1918.
- van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991;254:1643–1647.
- van der Bruggen P, Stroobant V, Vigneron N, et al. Peptide database: T cell-defined tumor antigens. *Cancer Immunol* 2013. <https://www.cancerimmunity.org/peptide/>
- Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. *Adv Cancer Res* 2006;95:1–30.
- Chinnasamy N, Wargo JA, Yu Z, et al. A TCR targeting the HLA-A\*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. *J Immunol* 2011;186:685–696.
- Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. *J Immunother* 2013;36:133–151.
- Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood* 2013;122:863–871.
- Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. *Science* 1994;264:716–719.
- Kawakami Y, Elyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. *J Immunol* 1995;154:3961–3968.
- Briehard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1993;178:489–495.
- Wang RF, Robbins PF, Kawakami Y, et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. *J Exp Med* 1995;181:799–804.
- Wang R-F, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. *J Exp Med* 1996;184:2207–2216.
- Kawakami Y, Elyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. *Proc Natl Acad Sci U S A* 1994;91:3515–3519.
- Coulie PG, Briehard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1992;180:55–62.
- Kawakami Y, Elyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. *J Exp Med* 1994;180:347–352.
- Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. *Nature* 2004;427:252–256.
- Carrington DM, Auffret A, Hanke DE. Polypeptide ligation occurs during post-translational modification of concanavalin A. *Nature* 1985;313:64–67.
- Paulus H. Protein splicing and related forms of protein autoprocessing. *Annu Rev Biochem* 2000;69:447–496.
- Vigneron N, Stroobant V, Chapiro J, et al. An antigenic peptide produced by peptide splicing in the proteasome. *Science* 2004;304:587–590.
- Warren EH, Vigneron NJ, Gavin MA, et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. *Science* 2006;313:1444–1447.
- Dalet A, Robbins PF, Stroobant V, et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. *Proc Natl Acad Sci U S A* 2011;108:E323–E331.
- Michaux A, Larrieu P, Stroobant V, et al. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. *J Immunol* 2014;192:1962–1971.
- Ikedo H, Lethe B, Lehmann F. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. *Immunity* 1999;6:199–208.
- Lundegaard C, Lamberth K, Hamdahl M, et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11. *Nucleic Acids Res* 2008;36:W509–W512.
- Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. *BMC Bioinformatics* 2005;6:132.
- Xue BH, Zhang Y, Sosman JA, et al. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. *Prostate* 1997;30:73–78.
- Horiguchi Y, Nukaya I, Okazawa K, et al. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. *Clin Cancer Res* 2002;8:3885–3892.
- Peoples GE, Goedegeburre PS, Smith R. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. *Proc Natl Acad Sci U S A* 1995;92:432–436.
- Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. *Cancer Res* 1998;58:4902–4908.
- Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. *Immunity* 1999;10:673–679.
- Parkhurst MR, Riley JP, Igarashi T, et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. *Clin Cancer Res* 2004;10:4688–4698.
- Weinschenk T, Gouttefangeas C, Schirle M, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. *Cancer Res* 2002;62: 5818–5827.
- Dutoit V, Herold-Mende C, Hilf N, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. *Brain* 2012;135:1042–1054.
- Walter S, Weinschenk T, Stenzl A, et al. Multipptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nat Med* 2012;18:1254–1261.
- Theobald M, Biggs J, Dittmer D, et al. Targeting p53 as a general tumor antigen. *Proc Natl Acad Sci U S A* 1995;92:11993–11997.
- Theoret MR, Cohen CJ, Nahvi AV, et al. Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. *Hum Gene Ther* 2008;19:1219–1231.
- Parkhurst M, Joo J, Riley JP, et al. Characterization of genetically modified T cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. *Clin Cancer Res* 2009;15: 169–180.
- Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Mol Ther* 2011;19:620–626.
- Wolfel T, Hauer M, Schneider J, et al. A p16INK4A-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. *Science* 1995;269:1281–1284.
- Robbins PF, El-Gamil M, Li YF, et al. A mutated B-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. *J Exp Med* 1996;183:1185–1192.
- Rubinfeld B, Robbins P, El-Gamil M. Stabilization of beta-catenin by genetic defects in melanoma cell lines. *Science* 1997;275:1790–1792.
- Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. *Semin Immunol* 1996;8:289–293.
- Cheever MA, Chen W, Disis ML, et al. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. *Ann N Y Acad Sci* 1993;690: 101–112.
- Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. *Cancer Res* 2012;72:1081–1091.
- Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeediting. *Nature* 2012;482: 400–404.
- Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat Med* 2013;19:747–752.
- van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J Clin Oncol* 2013;31:e439–e442.
- Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. *Science* 2014;344:641–645.
- Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. *N Engl J Med* 2002;347:1645–1651.
- Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* 2005;6:271–278.
- Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009;15:7412–7420.
- Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. *J Natl Cancer Inst* 2010;102:1388–1397.
- Morgan DA, Ruscetti FW, Callo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. *Science* 1976;193:1007–1008.

60. Smith KA, Gilbride KJ, Favata MF. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. *Nature* 1980;287:853–855.
61. Smith KA, Lachman LB, Oppenheim JJ, et al. The functional relationship of the interleukins. *J Exp Med* 1980;151:1551–1556.
62. Taniguchi T, Matsui H, Fujita T. Structure and expression of a cloned cDNA for human interleukin-2. *Nature* 1983;302:305–307.
63. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in *Escherichia coli*. *Science* 1984;223:1412–1414.
64. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant IL-2. *J Exp Med* 1985;161:1169–1188.
65. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin-2. II. Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. *J Immunol* 1985;135:2865–2875.
66. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485–1492.
67. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J Natl Cancer Inst* 1993;85:622–632.
68. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. *J Clin Oncol* 1993;11:661–670.
69. Rosenberg SA, Yang JC, White DE, et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. *Ann Surg* 1998;228:307–319.
70. Fyfe G, Fisher R, Sznol M, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose proleukin interleukin-2 therapy. *J Clin Oncol* 1995;13:688–696.
71. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. *Cancer J Sci Am* 2000;6:S55–S57.
72. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. *J Clin Oncol* 2003;21:3127–3132.
73. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999;17:2105–2116.
74. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000;6:S11–S14.
75. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 1998;4:321–327.
76. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med* 2011;364:2119–2127.
77. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. *Clin Cancer Res* 2012;18:2039–2047.
78. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. *J Clin Oncol* 2001;19:3477–3482.
79. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. *JAMA* 1994;271:907–913.
80. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. *Ann Surg* 1989;210:474–484.
81. Gemlo BT, Palladino Jr MA, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. *Cancer Res* 1988;48:5864–5867.
82. Pockaj BA, Yang JC, Lotze MT, et al. A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy. *J Immunother Emphasis Tumor Immunol* 1994;15:22–28.
83. Klempner MS, Noring R, Mier JW, et al. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. *N Engl J Med* 1990;322:959–965.
84. Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. *J Clin Oncol* 1989;7:7–20.
85. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. *J Immunother* 2001;24:287–293.
86. Kammula U, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. *Cancer* 1998;83:797–805.
87. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily—CTLA4. *Nature* 1987;328:267–270.
88. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. *J Exp Med* 1991;174:561–569.
89. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. *Immunity* 1994;1:405–413.
90. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. *J Exp Med* 1996;183:2541–2550.
91. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J Exp Med* 1999;190:355–366.
92. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. *Proc Natl Acad Sci U S A* 1998;95:10067–10071.
93. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proc Natl Acad Sci U S A* 2003;100:8372–8377.
94. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. *Ann Surg Oncol* 2005;12:1005–1016.
95. Maker AV, Yang JC, Sherry RM, et al. Inpatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. *J Immunother* 2006;29:455–463.
96. Beck KE, Blansfield JA, Tran KO, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 2006;24:2283–2289.
97. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. *J Immunother* 2004;27:478–479.
98. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–723.
99. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517–2526.
100. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. *Ann Oncol* 2013;24:2174–2180.
101. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. *J Immunother* 2007;30:825–830.
102. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. *Clin Cancer Res* 2010;16:1042–1048.
103. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol* 2013;31:616–622.
104. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. *Clin Cancer Res* 2013;19:5300–5309.
105. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. *Annu Rev Immunol* 2008;26:677–704.
106. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002;8:793–800.
107. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *J Clin Oncol* 2010;28:3167–3175.
108. Brahmer JR. Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? *Semin Oncol* 2014;41:126–132.
109. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol* 2014;32:1020–1030.
110. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013;369:122–133.
111. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013;369:134–144.
112. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366:2455–2465.
113. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. *Nat Rev Clin Oncol* 2014;11:24–37.
114. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. *Nat Med* 2004;10:909–915.
115. Klebanoff CA, Acquavella N, Yu Z, et al. Therapeutic cancer vaccines: are there yet? *Immunol Rev* 2011;239:27–44.
116. Slingluff CL, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100<sub>280-288</sub> peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. *Clin Cancer Res* 2001;7:3012–3024.
117. Schaad SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA\* A0201<sup>+</sup> melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte

- macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. *Clin Cancer Res* 2004;8:967–972.
118. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. *J Clin Oncol* 2000;18:3964–3973.
  119. Eder JP, Kantoff PW, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. *Clin Cancer Res* 2003;6:1632–1638.
  120. Lurquin C, Lethé B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. *J Exp Med* 2005;201:249–257.
  121. Marincola FM, Rivoltini L, Salgaller ML, et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. *J Immunother Emphasis Tumor Immunol* 1996;19:266–277.
  122. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. *Cancer J Sci Am* 1997;3:37–44.
  123. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010;363:422.
  124. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. *N Engl J Med* 1988;319:1676–1680.
  125. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nat Rev Immunol* 2012;12:269–281.
  126. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. *Blood* 1998;92:1549–1555.
  127. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. *J Natl Cancer Inst* 1994;86:1159–1166.
  128. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. *Science* 2002;298:850–854.
  129. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. *J Clin Oncol* 2008;26:5233–5239.
  130. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. *Nat Rev Clin Oncol* 2011;8:577–585.
  131. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science* 2006;314:126–129.
  132. Kochenderfer JN, Wilson WH, Janik E, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010;116:4099–4102.
  133. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725–733.
  134. Tiera MJ, Winnik FO, Fernandes JC. Synthetic and natural polycations for gene therapy: state of the art and new perspectives. *Curr Gene Ther* 2006;6:59–71.
  135. Birkholz K, Hombach A, Krug C, et al. Transfer of mRNA encoding recombinant immunoreceptor programs CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer. *Gene Ther* 2009;16:596–604.
  136. Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. *Mol Ther* 2006;13:151–159.
  137. Li L, Liu LC, Feller S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. *Cancer Gene Ther* 2010;17:147–154.
  138. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Res* 2010;70:9053–9061.
  139. Ivics Z, Izsvak Z. Transposons for gene therapy! *Curr Gene Ther* 2006;6:593–607.
  140. Singh H, Huls H, Kebriaei P, et al. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. *Immunol Rev* 2014;257:181–190.
  141. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med* 2003;348:255–256.
  142. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. *Proc Natl Acad Sci U S A* 1995;92:6733–6737.
  143. Maetzig T, Galla M, Baum C, et al. Gammaretroviral vectors: biology, technology and application. *Viruses* 2011;3:677–713.
  144. Schambach A, Swaney WP, van der Loo JC. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. *Methods Mol Biol* 2009;506:191–205.
  145. Hughes MS, Yu YYL, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. *Hum Gene Ther* 2005;16:457–472.
  146. Zhang X, Godbey WT. Viral vectors for gene delivery in tissue engineering. *Adv Drug Deliv Rev* 2006;58:515–534.
  147. Yu SS, Han E, Hong Y, et al. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination. *Gene Ther* 2003;10:706–711.
  148. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. *Blood* 2003;102:497–505.
  149. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMG2A activation after gene therapy of human beta-thalassaemia. *Nature* 2010;467:318–322.
  150. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood* 2009;114:535–546.
  151. Simpson AJ, Caballero OL, Jungbluth A, et al. Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer* 2005;5:625.
  152. Hofmann O, Caballero OL, Stevenson BJ, et al. Genome-wide analysis of cancer/testis gene expression. *Proc Natl Acad Sci U S A* 2008;105:20422–20427.
  153. Zhang Y, Wang Z, Liu H, et al. Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies. *J Immunother* 2003;26:461–467.
  154. Jungbluth AA, Antonescu CR, Busam KJ, et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or C17. *Int J Cancer* 2001;94:252–256.
  155. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci U S A* 1989;86:10024–10028.
  156. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat Med* 2008;14:1264–1270.
  157. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. *J Immunol* 2008;180:7028–7038.
  158. Morgan RA, Johnson LA, Davis JL, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. *Hum Gene Ther* 2012;23:1043–1053.
  159. Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. *J Clin Invest* 2010;120:3953–3968.
  160. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proc Natl Acad Sci U S A* 2009;106:3360–3365.
  161. Feugier P, Van HA, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005;23:4117–4126.
  162. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. *J Clin Oncol* 2011;29:544–550.
  163. Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. *JAMA* 2011;306:1874–1883.
  164. Van BK. Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. *Curr Opin Oncol* 2011;23:681–691.
  165. Van BK. Stem cell transplantation for indolent lymphoma: a reappraisal. *Blood Rev* 2011;25:223–228.
  166. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncol* 1998;16:2825–2833.
  167. Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? *Blood* 2012;120:4256–4262.
  168. Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. *Immunol Rev* 2014;257:107–126.
  169. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A* 1993;90:720–724.
  170. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. *Nat Rev Clin Oncol* 2013;10:267–276.
  171. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. *Cancer Discov* 2013;3:388–398.
  172. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. *Nat Rev Cancer* 2013;13:525–541.
  173. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 2013;5:177ra38.
  174. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. *Nat Med* 2003;9:279–286.



175. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Mol Ther* 2009;17:1453–1464.
176. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B lineage leukemia effect. *Blood* 2003;101:1637–1644.
177. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. *Hum Gene Ther* 2012;23:444–450.
178. Wang X, Naranjo A, Brown CE, et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. *J Immunother* 2012;35:689–701.
179. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* 2011;118:4817–4828.
180. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med* 2011;3:95ra73.
181. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2011;119:2709–2720.
182. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia* 2004;18:678–684.
183. Kochenderfer JN, Yu Z, Frasheri D, et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. *Blood* 2010;116:3875–3886.
184. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. *J Exp Med* 1982;155:1063–1074.
185. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. *J Exp Med* 2005;202:907–912.
186. Uckun FM, Jaszc W, Ambrus JL, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. *Blood* 1988;71:13–29.
187. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. *J Immunother* 2009;32:689–702.
188. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. *Clin Cancer Res* 2007;13:5426–5435.
189. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *J Clin Invest* 2011;121:1822–1826.
190. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–1518.
191. Jensen MC, Poppellew L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. *Biol Blood Marrow Transplant* 2010;16:1245–1356.
192. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. *Blood* 2008;112:2261–2271.
193. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. *Blood* 2012;119:3940–3950.
194. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. *Blood* 2013;121:1165–1174.
195. Giordano Attianese GM, Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. *Blood* 2011;117:4736–4745.
196. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen RORI can be targeted with T cells modified to express a RORI-specific chimeric antigen receptor. *Blood* 2010;116:4532–4541.
197. Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. *Blood* 2006;108:3890–3897.
198. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. *Clin Cancer Res* 2013;19:2048–2060.
199. Peinert S, Prince HM, Guru PM, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. *Gene Ther* 2010;17:678–686.
200. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. *Mol Ther* 2013;21:2122–2129.
201. Mardiros A, Dos SC, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. *Blood* 2013;122:3138–3148.
202. Savoldo B, Rooney CM, Di SA, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. *Blood* 2007;110:2620–2630.
203. Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. *Cancer Res* 1998;58:1116–1119.
204. Shaffer DR, Savoldo B, Yi Z, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood* 2011;117:4304–4314.
205. Xue SA, Gao L, Hart D, et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. *Blood* 2005;106:3062–3067.
206. Nagai K, Ochi T, Fujiwara H, et al. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. *Blood* 2012;119:368–376.
207. Spranger S, Jeremias I, Wilde S, et al. TCR-transgenic lymphocytes specific for HMMR/Rhannitumor limit outgrowth in vivo. *Blood* 2012;119:3440–3449.
208. Hale GA, Shrestha S, Le-Rademacher J, et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. *Biol Blood Marrow Transplant* 2012;18:1036–1043.
209. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. *Blood* 2013;122:4129–4139.
210. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirection virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. *Blood* 2013;122:2965–2973.
211. Traversari C, Markt S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. *Blood* 2007;109:4708–4715.
212. Tey S, Dotti G, Rooney CM, et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. *Biol Blood Marrow Transplant* 2007;13:924.
213. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. *Lancet Oncol* 2009;10:489–500.
214. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. *N Engl J Med* 2011;365:1673–1683.